Sunset Begins For Roche's Herceptin As Amgen/Allergan Biosimilar Launches
Executive Summary
Amgen and Allergan launched the first US biosimilar for Roche's Herceptin – and the Swiss pharma's Avastin – at a 15% discount to the brand-name products' list prices. Scrip's infographic reviews Herceptin's past and its future competitors.
Amgen Inc. and Allergan PLC launched the first US biosimilars for Roche's Herceptin (trastuzumab) and Avastin (bevacizumab) on 18 July, also marking the first oncology biosimilar launches in the US.
Scrip reviewed Herceptin's rise and its coming fall in anticipation of near-term biosimilar product market entry, which wasn't expected until later this year or possibly in early 2020. Both Kanjinti (trastuzumab-anns) and Mvasi (bevacizumab-awwb) are priced at 15% discounts to Herceptin's and Avastin's list prices.